Aquacel Hypersensitivity Dressing in TJAs
| Condition | Contact Allergic Dermatitis, Adverse Skin Reaction |
|---|---|
| Phase | Phase 4 |
| Sponsor | Rush University Medical Center |
| Status | Completed |
| Enrollment | 457 participants |
| Interventions | Aquacel dressing |
| Start date | Jun 18, 2023 |
| Completion date | Nov 1, 2024 |
| Results posted | Aug 4, 2026 |
Summary
The aim of this multi-surgeon, single institution study is to prospectively evaluate the incidence of allergic contact dermatitis (ACD) following application of AQUACEL Ag, a silver-containing hydrofiber dressing, in total hip and knee arthroplasty patients. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
Number of Participants With Contact Allergic Dermatitis or Adverse Skin Reaction at 2 Weeks Post Surgery
| Arthroplasty-naïve Aquacel Group | 5 Participants |
|---|---|
| Prior Aquacel Group | 3 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen
- BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort — Women's College Hospital